Abstracts tagged "risk assessment"

Abstract Number: 1151 • ACR Convergence 2024
Clinical Characterization and Recurrence Prediction Model for Immune-Mediated Necrotizing Myopathy
Beibei Cui¹, Hongjiang Liu², Geng Yin³ and Qibing Xie⁴, ¹Rheumatology and Immunology, Chengdu, China (People's Republic), ²West China Hospital, Sichuan University, Chengdu, China (People's Republic), ³Department of Rheumatology and Immunology, chengdu, China (People's Republic), ⁴Department of Rheumatology and Immunology, Chengdu, Sichuan, China
Background/Purpose: The primary objective of this study was to comprehensively analyze the clinical characteristics of immune-mediated necrotizing myopathy (IMNM) and develop a reliable recurrence prediction…
Abstract Number: 1918 • ACR Convergence 2024
Exploring the Childhood Opportunity Index and Distance to Care in a Cohort of Children with Rheumatic Disease
Kristina Ciaglia¹ and Alaina Beauchamp², ¹UT Southwestern Medical Center and Scottish Rite for Children, Dallas, TX, ²UT Southwestern Medical Center, Dallas
Background/Purpose: Children from disadvantaged neighborhoods and socioeconomic backgrounds experience worse outcomes and delays in care.¹ The Childhood Opportunity Index (COI) is a multidimensional validated tool…
Abstract Number: 0444 • ACR Convergence 2024
Deep Serologic Profiling Identifies Novel Autoantibodies Associated with Fetal Atrioventricular Block
Philip Carlucci¹, Robert Clancy², Mala Masson³, Colin Phoon⁴, Ashley Roman⁴, Peter Izmirly⁵, Amit Saxena⁶, H Michael Belmont⁴, Christina Penfield⁴, Young Mi Lee⁴, Julie Nusbaum⁷, Andrew Rubenstein⁴, Ruben Acherman⁸, Elena Sinkovskaya⁹, Alfred Abuhamad⁹, Karla Bermudez-Wagner⁹, Majd Makhoul¹⁰, Gary Satou¹¹, Whitnee Hogan¹², Nelangi Pinto¹³, Anita Moon-Grady¹⁴, Lisa Howley¹⁵, Mary Donofrio¹⁶, Anita Krishnan¹⁶, Jaclyn Phillips¹⁷, Stephanie Levasseur¹⁸, Miwa Geiger¹⁹, Erin Paul²⁰, Sonal Owens²¹, Kristopher Cumbermack²², Jyothi Matta²³, Gary Joffe²⁴, Christopher Lindblade²⁵, Carl Weiner²⁶, Caitlin Haxel²⁷, Katherine Kohari²⁸, Joshua Copel²⁸, James Strainic²⁹, Tam Doan³⁰, Shreya Sheth³⁰, Stacy Killen³¹, Theresa Tacy³², Michelle Kaplinski³², Nicola Fraser⁴, Kelly Ruggles³³, Bettina Cuneo³⁴ and Jill Buyon³⁵, ¹New York University School of Medicine, New York, NY, ²Columbia University Medical Center, New York, NY, ³NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁴NYU Langone Health, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷NYU Langone Hospital - Long Island, Internal Medicine - Rheumatology, Mineola, NY, ⁸Children's Heart Center, Las Vegas, NV, ⁹Eastern Virginia Medical School, Norfolk, VA, ¹⁰Atrium Health Levine Children's Hospital, Charlotte, NC, ¹¹University of California Los Angeles, Los Angeles, CA, ¹²University of Utah, Salt Lake City, UT, ¹³Seattle Children's Hospital, Seattle, WA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹⁶Children's National Hospital, Washington, DC, ¹⁷George Washington University, Washington, DC, ¹⁸Columbia University, New York, NY, ¹⁹Mount Sinai School of Medicine, New York, NY, ²⁰Atlantic Health System, Morristown, NJ, ²¹University of Michigan, Ann Arbor, MI, ²²University of Kentucky, Lexington, KY, ²³University of Louisville, Louisville, KY, ²⁴Perinatal Associates of New Mexico, Albuquerque, NM, ²⁵Phoenix Children's Hospital, Phoenix, AZ, ²⁶Dignity Health, Phoenix, AZ, ²⁷University of Vermont Children's Hospital, Burlington, VT, ²⁸Yale University, New Haven, CT, ²⁹UH Rainbow Babies, Cleveland, OH, ³⁰Baylor College of Medicine, Houston, TX, ³¹Vanderbilt University, Nashville, TN, ³²Stanford University, Stanford, CA, ³³NYU Grossman School of Medicine, Brooklyn, NY, ³⁴University of Arizona College of Medicine, Tucson, AZ, ³⁵New York University Grossman School of Medicine, New York, NY
Background/Purpose: Maternal anti-SSA/Ro52/60kD autoantibodies are necessary for the development of fetal atrioventricular block (AVB) but titers alone are not sufficient to predict the likelihood of…
Abstract Number: 1192 • ACR Convergence 2024
Relationship Between Measures of Fat Mass and Knee Osteoarthritis Incidence: The Multicenter Osteoarthritis (MOST) Study
Kristine Godziuk¹, Sarah Tilley², mike LaValley³, Douglas Kiel⁴, Michael Nevitt⁵, C.E. Lewis⁶, James Torner⁷ and Tuhina Neogi², ¹University of Alberta, Edmonton, AB, Canada, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Hebrew SeniorLife and Department of Medicine Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ⁵UCSF, Orinda, CA, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷University of Iowa, Iowa City
Background/Purpose: Obesity [defined by body mass index (BMI) ≥30 kg/m2] is an established risk factor for incident radiographic knee OA (ROA). However, the relative contributions…
Abstract Number: 1956 • ACR Convergence 2024
Artificial Intelligence Enhanced Analysis of Nailfold Capillaries by Dermatoscopy in Rheumatology Centers
Genessis Maldonado¹, Eduardo Ramos-ibañez², Borja del Carmelo Gracia-Tello³, Radic Mislav⁴ and Tracy Frech¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Zaragoza, Zaragoza, Spain, ³Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain, ⁴University Hospital of Split, Split, Croatia
Background/Purpose: The use of dermatoscopes in rheumatology has been established for several years. However, the application of artificial intelligence for the detection of abnormalities in…
Abstract Number: 0462 • ACR Convergence 2024
Circulating Mediators of Endothelial Dysfunction as Predictors of Incident Heart Failure in Rheumatoid Arthritis
Tate Johnson¹, Michael Duryee¹, Carlos Hunter¹, Punyasha Roul², Joshua Baker³, grant Cannon⁴, Beth Wallace⁵, Paul Monach⁶, Andreas Reimold⁷, Gail Kerr⁸, Isaac Smith⁹, John Richards¹⁰, Katherine Wysham¹¹, Gary Kunkel¹², Iris Lee¹³, Daniel Anderson¹⁴, Geoffrey Thiele¹, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁶VA Boston Healthcare System, Boston, MA, ⁷Dallas VA Medical Center, Dallas, TX, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹Duke University Hospital, Durham, NC, ¹⁰Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ¹²University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴University of Nebraska Medical Center, Durham, NC
Background/Purpose: Endothelial dysfunction, leading to myocardial inflammation and dysfunction, may drive a heightened risk of heart failure (HF) in people with rheumatoid arthritis (RA). Circulating…
Abstract Number: 1202 • ACR Convergence 2024
Harnessing MicroRNA and Machine/Deep Learning for Early Prediction of Knee Osteoarthritis Structural Progression
Afshin Jamshidi¹, Osvaldo Espin-Garcia², Thomas G. Wilson³, Ian Loveless³, Jean-Pierre Pelletier¹, Amanda Ali⁴ and Johanne Martel-Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Department of Epidemiology and Biostatistics, University of Western Ontario; Dalla Lana School of Public Health and Department of Statistical Sciences, University of Toronto; Department of Biostatistics, Schroeder Arthritis Institute; Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Henry Ford Health + Michigan State University Health Sciences, Detroit, MI, ⁴Henry Ford Health + Michigan State University Health Sciences; Center for Molecular Medicine and Genetics, Wayne State University, Montreal, QC, Canada
Background/Purpose: The development of knee osteoarthritis (OA) is generally characterized by a slow evolution. However, its progression and severity may occur rapidly in some individuals.…
Abstract Number: 2018 • ACR Convergence 2024
Non-adherence to Urate Lowering Therapy in Gout After 5 Years Is Related to Poor Outcomes – Results from the NOR-Gout Study
Tillmann Uhlig¹, Lars F Karoliussen¹, Joseph Sexton², Sella A. Provan², Espen A. Haavardsholm³, Nicola Dalbeth⁴ and Hilde B Hammer¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: People with gout need to adhere to medication over time to achieve good outcomes. We assessed self-reported adherence to medication with urate lowering therapy…
Abstract Number: 0637 • ACR Convergence 2023
Comparison of Four Risk Stratification Models for Prediction of Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in the EUSTAR Cohort
Hilde Jenssen Bjørkekjær¹, Cosimo Bruni², Cathrine Brunborg³, Patricia Carreira⁴, Paolo Airò⁵, Carmen Pilar Simeon-Aznar⁶, Marie-Elise Truchetet⁷, Alessandro Giollo⁸, Alexandra Balbir-Gurman⁹, Mickael Martin¹⁰, Christopher Denton¹¹, Armando Gabrielli¹², Havard Fretheim¹³, Imon Barua¹³, Helle Bitter¹⁴, Oyvind Midtvedt¹³, Torhild Garen¹⁵, Kaspar Broch¹⁶, Arne Andreassen¹⁷, Yoshiya Tanaka¹⁸, Gabriela Riemekasten¹⁹, Ulf Müller-Ladner²⁰, marco Matucci Cerinic²¹, Ivan Castellvi²², Elise Siegert²³, Eric Hachulla²⁴, Oliver Distler² and Anna-Maria Hoffmann-Vold¹³, ¹Department of Rheumatology, Hospital of Southern Norway, Kristiansand & University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ⁶Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, ⁷Bordeaux University Hospital, Bordeaux, France, ⁸University of Verona, Rheumatology Section, Department of Medicine, Verona, Italy, Verona, Italy, ⁹Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁰Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, ¹¹University College London, London, United Kingdom, ¹²Ospedali Riuniti Marche, Ancona, Italy, ¹³Oslo University Hospital, Oslo, Norway, ¹⁴Sorlandet sykehus, Kristiansand, Norway, ¹⁵Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, ¹⁶Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, KG Jebsen center, Institute for Experimental Medical Research, University of Oslo, Oslo, Norway, ¹⁷Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, ¹⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ²⁰Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ²¹Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ²²Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ²³Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ²⁴University of Lille, Lille, France
Background/Purpose: The 2022 ESC/ERS Guidelines recommend comprehensive risk stratification at diagnosis of pulmonary arterial hypertension (PAH) to guide optimized management.1Several risk stratification tools have been…
Abstract Number: 2267 • ACR Convergence 2023
Explainable Machine Learning to Predict Hospitalized Infection in Patients with Systemic Lupus Erythematosus
Hsin-Hua Chen¹ and Wen-Nan Huang², ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Veterans General Hospital, College of Medicine National Chung Hsing University, Department of Business Administration, Ling-Tung University, Taichung, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 1.85-fold higher risk of all-cause mortality and a 2.74 fold higher risk of infection-related mortality compared…
Abstract Number: 0638 • ACR Convergence 2023
Application of the 2022 European Society of Cardiology (ESC) Risk Assessment Model in Australian and Singaporean Systemic Sclerosis Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH)
Zoe Brown¹, Dylan Hansen², Wendy Stevens³, Nava Ferdowsi⁴, laura ross⁵, Alannah Quinlivan⁶, Joanne Sahhar⁷, Gene-Siew Ngian⁷, Diane Apostolopoulos⁷, Jennifer G Walker⁸, Susanna Proudman⁹, Gim Gee Teng¹⁰, Andrea Hsiu Ling Low¹¹, Kathleen Morrisroe¹² and Mandana Nikpour¹³, ¹The University of Melbourne, Armadale, Australia, ²Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, ³Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, ⁴St Vincents Hospital, Kew, Australia, ⁵St. Vincent's Hospital Melbourne, Fitzroy, Australia, ⁶St Vincent's Hospital Melbourne, Highett, Australia, ⁷Monash Health and Monash University, Clayton, Australia, ⁸Royal Adelaide Hospital, Adelaide, Australia, ⁹Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, ¹⁰Alexandra Hospital, Department of Medicine, Division of Rheumatology, National University Health System, Singapore, Singapore, ¹¹Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ¹²The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, ¹³The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) patients can be stratified as low, intermediate, or high risk of 1-year mortality based on clinical, biochemical and haemodynamic prognostic…
Abstract Number: 2323 • ACR Convergence 2023
An Electronic Health Record-Based Algorithm for Predicting Systemic Lupus Erythematosus Flares: Integrating Clinical Factors and Social Determinants of Health
Yu Huang¹, Lixia Yao², zhengkang Fan³, Jingchuan Guo¹ and Jiang Bian¹, ¹University of Florida, Gainesville, FL, ²Polygon Health Analytics LLC, Chalfont, PA, ³University of Florida, Gainsville, FL
Background/Purpose: Systemic lupus erythematosus (SLE) has a relapsing-remitting course, with patients experiencing disease activity flares over time. Flares and prolonged disease activity are associated with…
Abstract Number: 0654 • ACR Convergence 2023
Comparison of Cardiovascular Risk in Patients with Systemic Sclerosis and the General Population
Sabina Oreska¹, Hana Storkanova¹, Jaroslav Kudlicka², Vladimir Tuka², Ondrej Mikes², Zdislava Krupickova², Martin Satny², Eva Chytilova², Jan Kvasnicka², Maja Spiritovic³, Barbora Hermankova⁴, Petr Cesak⁵, Marian Rybar⁶, Karel Pavelka⁷, Ladislav Senolt⁸, Radim Becvar⁹, Jiri Vencovsky¹, Michal Vrablik² and Michal Tomcik¹, ¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁴Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁵Department of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁶Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic, ⁷Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic, ⁹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: Patients with systemic sclerosis (SSc) may be burdened by increased cardiovascular (CV) risk due to accelerated atherosclerosis (ATS) due to systemic inflammation, and vascular…
Abstract Number: 2362 • ACR Convergence 2023
Identification of Protein Biomarkers Associated with the Severity and Risk of Progression of Interstitial Lung Disease in VEDOSS and Established Systemic Sclerosis Patients
Thierry Sornasse¹, Vishal Kakkar², Rebecca Ross³, Sunhwa Kim⁴ and Francesco Del Galdo⁵, ¹AbbVie, Inc., North Chicago, IL, ²University of Leeds, Leeds, United Kingdom, ³Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁴AbbVie, Inc., South San Francisco, CA, ⁵University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Pulmonary Fibrosis (PF) is one of the primary causes of systemic sclerosis (SSc)-related death. Hence, monitoring and predicting the course of PF in SSc…
Abstract Number: 0015 • ACR Convergence 2023
Genetic Predisposition to a Positive Antinuclear Antibody Test Is Not Associated with Increased Risk of Disease
Gul Karakoc¹, Ge Liu¹, Jacy Zanussi², Cecilia Chung², Jorge Gamboa¹, Jonathan Mosley¹, Nancy Cox¹, C. Michael Stein¹ and Vivian Kawai¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Miami, Miami, FL
Background/Purpose: Antinuclear antibodies (ANA) are biomarkers that are frequently used in the diagnosis of common autoimmune (AI) disorders, but are also present in ~12-20% of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].